top of page
OXYPREEM Logo

OXY-PREEM-Trial

Does the use of 60% vs 30% oxygen reduce respiratory support in 32+0-35+6 week preterm infants? 

Infographic OXYPREEM-Trial

Population

Preterm infants born at 32+0-35+6 weeks’ gestation

 

Primary Objective

Does resuscitation with 60% versus 30% initial oxygen reduce the need for respiratory support within the first hour after birth in moderate to late preterm infants (32+0-35+6 weeks’ gestation)?

 

Primary Hypothesis: Population (P), Intervention (I), Comparison (C), Outcome (O), Timeline (T):  

P: In preterm infants born at 32+0-35+6 weeks’ gestation who require breathing support at delivery.  

I: does initiating resuscitation with a higher oxygen concentration of 60%

C: compared to initiating with a lower oxygen concentration of 30%

O: increase or decrease the incidence of respiratory support

T: within the 1st hour after birth?  

Design and Sample Size

This prospective cluster-crossover design, unmasked randomized controlled trial (RCT) comparing two oxygen concentrations at initiation of resuscitation. 1,520 -  760 control / 760 intervention

 

Inclusion Criteria

i) Infants with gestational age between 32+0-35+6 weeks based on best available obstetrical estimate, requiring respiratory support

ii) Infants designated to receive full resuscitation, i.e., no parental request or pre-determined decision to provide only comfort care at birth

iii) No known major congenital or chromosomal malformation.

Exclusion Criteria 

i) Infant born outside of study centers and transported to centers after delivery.

 

Efficacy Endpoints 

Primary:

  • Respiratory support within the 1st hour after birth

Secondary: 

  • Delivery room interventions

  • Admission temperature

  • Neonatal UTSTEIN

  • Mechanical ventilation

  • Infection/sepsis

  • Pneumothorax

  • Brain injury as indicated by abnormal neuroimaging

  • among others

Safety Evaluations 

Adverse events

 

Statistical Methodology

Interim analyses will be conducted when 33% and 66% infants are participants complete primary outcome. The final analysis will be conducted after the study is completed, unblinded, and the database is released for analysis.

Clinical Centers

Canada

Enrolment Period: 3 years

ClinicalTrials.Gov Trial: 

© 2014-2026 by CSAR

  • Spotify
  • Twitter Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
bottom of page